http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5726330-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C401-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00 |
| filingDate | 1993-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1998-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a73473595c822e34f930b2c5c6566cd9 |
| publicationDate | 1998-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5726330-A |
| titleOfInvention | Highly crystalline 22-oxavitamin D derivatives |
| abstract | PCT No. PCT/JP93/01490 Sec. 371 Date Apr. 17, 1995 Sec. 102(e) Date Apr. 17, 1995 PCT Filed Oct. 18, 1993 PCT Pub. No. WO94/08958 PCT Pub. Date Apr. 28, 1994Highly crystalline vitamin D derivatives are represented by the formula: <IMAGE> (where R1 is a straight or branched C4-C9 alkyl group optionally having a hydroxyl group; R2 and R3 which may be the same or different are each an acyl group), 22-oxavitamin D derivatives of high purity are produced by hydrolyzing said compounds which derivatives are useful as pharmaceuticals. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110940747-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014051875-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6080879-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110940747-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6121469-A |
| priorityDate | 1992-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.